ArticleMedical & biological engineering & computing2026
VMDiff: A novel hybrid CNN-Mamba generative framework for retinal phenotype image enhancement.
Article in Medical & biological engineering & computing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Retinal phenotype is crucial for the diagnosis of ophthalmic diseases. Although deep learning models exhibit strong generative capability and detailed reconstruction, they struggle to simultaneously capture fine local details and long-range global dependencies, resulting in poor phenotypic enhancement. To overcome these limitations, we propose VMDiff, a hybrid generative framework based on diffusion models that synergistically integrates CNN and Mamba architectures to enhance retinal images while preserving both local and global features. Specifically, we introduce a high-frequency extraction module (HFEM) with a dedicated high-frequency consistency loss to retain fine structural details more effectively. Moreover, we propose a progressive loss mechanism to decouple the optimization objectives, effectively balancing pixel-level accuracy and perceptual quality. Extensive experiments on synthetically degraded versions of multiple public datasets demonstrate that VMDiff significantly improves image quality. Notably, it achieves highly competitive performance on EyePACS (with a comparable PSNR of 27.8448 and a significantly superior SSIM of 0.9428), while setting state-of-the-art records on DRIVE and IDRiD with PSNR values of 26.7520 and 27.7434, and SSIM scores of 0.9609 and 0.9266, respectively. Further validation on the DRIVE dataset via a vessel segmentation task confirms VMDiff’s efficacy in downstream biomedical analysis, yielding the highest AUC (0.9715), ACC (0.9556), and IoU (0.9516), thereby highlighting its clinical potential.
Indexed as
Identifiers
42053739What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.